16 results about "Viral pneumonia" patented technology

The application discloses application of an aloe oral liquid in preparation of a medicine for treating acute viral pneumonia. A preparation method of the aloe oral liquid comprises the following steps: after fresh aloe leaves are washed and peeled, the fresh aloe leaves are scraped to prepare fresh aloe gel; the fresh aloe gel liquid is placed in a light reaction tank, and is subjected to blue light, red light and no light alternately under low-temperature conditions; the fresh aloe gel after light treatment is pumped into a decocting and concentrating tank, and is concentrated to a supernatant with a density of 1.10 kg / m 3 1.2 kg / m 3 between, is filled and sealed after cooling, and is sterilized to obtain the aloe oral liquid. The application promotes clinical indications of fresh aloe leaves, provides a new drug selection for clinical treatment of acute viral pneumonia, provides a technical reference for industrial production of fresh aloe leaf medicine products, and promotes inheritance and innovation of traditional Chinese medicines with clinical application as a foothold.

This invention provides a traditional Chinese medicine composition for treating viral pneumonia in calves, its preparation method, and its application, belonging to the field of veterinary drug technology. The traditional Chinese medicine composition provided by this invention comprises the following raw materials in parts by weight: 15-20 parts of Gentiana scabra, 15-20 parts of Gardenia jasminoides, 15-20 parts of Scutellaria baicalensis, 10-15 parts of Bupleurum chinense, 25-35 parts of Rehmannia glutinosa, 25-35 parts of Plantago asiatica, 15-20 parts of Alisma plantago-aquatica, 25-35 parts of Akebia trifoliata, 10-15 parts of Angelica sinensis, 25-35 parts of Smilax glabra, 15-20 parts of Dioscorea hypoglauca, 25-35 parts of Dictamnus dasycarpus, and 10-15 parts of Glycyrrhiza uralensis (processed). The traditional Chinese medicine composition of this invention can effectively treat viral pneumonia in calves, and also has advantages that antibiotics cannot possess, such as being green and safe, residue-free, having few toxic side effects, low cost, convenient production, and being less likely to produce drug-resistant bacteria.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The application relates to an application of a traditional Chinese medicine composition in a drug for viral pneumonia, which comprises 10-15 parts of wind-preventing, 10-15 parts of perilla leaf, 2-6 parts of Ephedra, 7-9 parts of Schisandra chinensis, 7-9 parts of white ginkgo, 7-9 parts of bitter almond, 7-9 parts of purple aster, 7-9 parts of dogwood fruit and 7-9 parts of lily of the valley. The traditional Chinese medicine composition can obviously inhibit the increase of the lung index of respiratory syncytial virus (RSV) infected mice and has a better treatment effect on viral pneumonia.

The application discloses a drug delivery system targeting lung alveolus microenvironment oxidation and reduction as well as a preparation method and application thereof, and comprises nanoparticles self-assembled by amphiphilic GSH-(oxi)PEI-PCL polymers, wherein the nanoparticles load fat-soluble drugs or fluorescent dyes, GSH in the amphiphilic GSH-(oxi)PEI-PCL polymers is connected with (oxi)PEI-PCL through a disulfide bond, and the (oxi)PEI-PCL is PEI-PCL subjected to partial oxidation. The pharmacodynamic test result shows that the drug delivery system can realize passive targeting aggregation of drugs in a lesion and microenvironment oxidation and reduction sensitive distribution, meanwhile, the drug delivery system shows an antioxidation effect in a lesion microenvironment and intracellular, realizes more accurate drug distribution effect and in-vivo treatment effect, and provides a new drug route for treatment of lung diseases such as premature lung dysplasia, bacterial / viral pneumonia or burn inhalation lung injury.

The use of cellular microparticles in the treatment of respiratory viral pneumonia has been disclosed. Tumor cell-derived microparticles (MPs) include cellular vesicles released by apoptotic tumor cells. The cellular vesicles express spike protein-binding receptors on their surfaces. MPs have high biosafety. In addition, it has been found that the receptors on the surface of microparticles have virus adsorption ability, and macrophages can efficiently take up MPs, which can be used to treat viral pneumonia.

This invention relates to the field of compound essential oils of traditional Chinese medicine, and particularly to a compound essential oil of traditional Chinese medicine for the adjuvant intervention against Streptococcus pneumoniae and its preparation method. The raw materials include the following by weight: 3-8 parts of patchouli essential oil; 2-6 parts of clove essential oil; 2-5 parts of costus root essential oil; 2-6 parts of nard essential oil; 3-7 parts of calamus essential oil; 1-4 parts of asarum essential oil; 3-8 parts of peppermint essential oil; 2-6 parts of artemisia essential oil; 3-7 parts of eupatorium essential oil; 45-80 parts of base oil; 2-5 parts of solubilizer; and 1-3 parts of penetration enhancer. This invention addresses the core issues of "respiratory inflammation, sputum accumulation, and decreased body defense" caused by Streptococcus pneumoniae. Through the scientific formulation of active molecules from nine kinds of Chinese herbal essential oils, a comprehensive synergistic system is formed, which has the functions of "antibacterial and antiviral, anti-inflammatory and lung-clearing, expectorant and cough-relieving, and enhanced defense." It features strong synergistic activity of active molecules, high specificity, high retention and utilization rate of active molecules, safe and convenient use, wide applicability, and simple preparation process.

The present invention refers to an in vitro method for the diagnosis of a Mycoplasma pneumoniae infection and / or for the differential diagnosis between a Mycoplasma pneumoniae pneumonia and other bacterial or viral pneumonias and / or for assessing whether to treat a patient suffering from pneumonia with a macrolide antibiotic.

The invention belongs to the technical field of medicines, and discloses a composition for improving bioavailability of arecoline. Specifically, the composition specifically comprises arecoline and magnolol, and the weight ratio of arecoline to magnolol in the pharmaceutical composition is (1: 0.1)-(1: 15). According to the composition, the in-vivo bioavailability of the arecoline can be remarkably improved, the half-life period and the average residence time of the arecoline can be prolonged, the application range of the arecoline is widened, and the treatment effect of the arecoline on diseases such as tapeworm infection, abdominal distension, diarrhea, edema, cancer, Alzheimer's disease, cerebral apoplexy, epilepsy and viral pneumonia can be better exerted.

The application discloses a traditional Chinese medicine composition, which comprises the following raw materials: shengteng, honeysuckle, chrysanthemum, peppermint, forsythia, platycodon, radix peucedani, anemarrhena, radix pini, radix styracis, scabrousfruit, calcined turtle, artemisia, apricot kernel, gypsum, ephedra, licorice, ophiopogon, radix scrophulariae, radix bupleuri. The application further discloses a preparation containing the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for treating viral pneumonia. The traditional Chinese medicine composition has a rapid relieving effect on high fever and cough caused by viral pneumonia, can effectively treat viral pneumonia, and relieve the pain of patients. The safety and effectiveness of the traditional Chinese medicine composition are proved through years of clinical practice.

Abstract: This invention discloses a traditional Chinese medicine composition (Da Zhuque Decoction) with multi-target antiviral and anti-inflammatory activities, its preparation method, and its application. The composition consists of the following raw materials in parts by weight: Alisma plantago-aquatica 2-4 parts, Prunus armeniaca 4-6 parts, Chrysanthemum indicum 4-6 parts, Artemisia annua 5-7 parts, Morus alba leaf 5-7 parts, Gypsum 5-7 parts, Poria cocos 7-9 parts, Scutellaria baicalensis 8-10 parts, Rehmannia glutinosa 8-10 parts, Plantago asiatica 11-13 parts, Taraxacum mongolicum 14-16 parts, and Glycyrrhiza uralensis 3-5 parts. This invention overcomes the limitations of traditional qualitative formulation of traditional Chinese medicines. By limiting the specific synergistic ratio of artemisinin and baicalin (1:2.5~3.0), it achieves highly efficient inhibition of respiratory viruses (IC50=12.5μg / mL) and significant downregulation of inflammatory factors (IL-6, TNF-α). Meanwhile, the preparation process of "plaster decoction first - licorice extraction alone" solves the problem of easy decomposition of heat-sensitive components, increasing the artemisinin retention rate to over 95%. This invention has a clear material basis, controllable quality, and is suitable for preparing drugs or health products for the prevention and treatment of viral pneumonia.

The invention discloses a kit and method for detecting myxovirus drug-resistant protein A based on polypeptide and application, and belongs to the technical field of proteomics. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 29. The polypeptide is obtained based on enzymolysis of an MxA standard substance and screening, a standard curve is established by utilizing the polypeptide and isotope labeled polypeptide, a biological sample is further subjected to enzymolysis to obtain a peptide fragment sample, and MxA in the biological sample can be quantified by detecting the content of the polypeptide in the peptide fragment sample. By utilizing the method disclosed by the invention, the MxA in the biological sample can be rapidly quantified, so that the viral pneumonia and the bacterial pneumonia are diagnosed and distinguished, and the accuracy rate is high.

This invention belongs to the field of traditional Chinese medicine pharmaceutical technology, specifically relating to the use of loliolide, a sesquiterpene compound, in the treatment of viral pneumonia. The invention isolates and extracts loliolide from *Lysimachia christinae*. Whole-animal experiments have confirmed that this compound has a good therapeutic effect on H1N1 influenza A virus-induced viral pneumonia in mice, significantly improving body weight, lung index, lung inflammation, viral titer, and pathological changes in virus-infected mice. Loliolide can be further used to prepare new drugs for the treatment of viral pneumonia.

The application provides a traditional Chinese medicine effective part composition, a preparation method and application thereof. The traditional Chinese medicine effective part composition comprises the following weight parts of effective part medicines of traditional Chinese medicine compound preparation medicines: 125-2000 parts of polysaccharide parts, 0.625-2.5 parts of alkaloid parts, 6.25-100 parts of volatile oil parts and 6.25-100 parts of total glycoside parts. The traditional Chinese medicine compound preparation medicines comprise Poria cocos, Glycyrrhiza uralensis Fisch., Citrus aurantium, Platycodon grandiflorum, Bupleurum smithii, Gypsum fibrosum, Anemarrhena asphodeloides, Peucedanum decursivum, Notopterygium incisum, Cimicifuga foetida, Saposhnikovia divaricata, Schizonepeta, Chuanxiong, Pueraria lobata, Mentha haplocalyx, Lonicera japonica, Forsythia suspensa, Agastache rugosa, Ephedra sinica and Atractylodes lancea. The application further discloses a preparation method of the traditional Chinese medicine effective part composition and application of the traditional Chinese medicine effective part composition in preparing medicines for treating influenza and viral pneumonia. The influenza is influenza A, and the viral pneumonia is pneumonia induced by influenza A virus. A medicine for treating influenza and viral pneumonia comprises the traditional Chinese medicine effective part composition.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in inhibiting influenza virus or treating influenza viral pneumonia. This invention found that banana fruit extract has a certain inhibitory effect on influenza virus in vitro, maintaining its effect for 48 hours after viral infection. In vivo antiviral tests showed that banana fruit extract effectively improved viral pneumonia caused by influenza virus, with a significant difference compared to the virus control group. Therefore, banana fruit extract has a certain inhibitory effect on influenza virus both in vitro and in vivo, and can effectively improve viral pneumonia caused by influenza virus in mice, demonstrating good application potential and warranting further in-depth research and clinical application. This provides technical support for subsequent research and application.